COSCIENS Biopharma Inc. has seen notable price movements recently, reflecting changes in its corporate structure and financial results.
This week, COSCIENS Biopharma Inc. (CSCI.TO) is experiencing a slight uptick in its stock price, with a 1.99% increase over the past week. Despite no major news this week, recent corporate actions and financial results continue to shape investor sentiment.
Investor takeaway: Investors should remain cautious with COSCIENS Biopharma, especially given its recent share capital amendment and the company's significant drop from its moving averages. Keeping an eye on the company's financial health and operational developments will be crucial moving forward.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
COSCIENS Biopharma Inc.
CSCI.TO
CSCI.TO
COSCIENS Biopharma Inc.
WealthAwesomeMarket cap
$8.17M
52W high
$14.80
52W low
$1.10
1W change
+1.99%
Beta
1.90
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CSCI's historical volatility
30-Day Vol
574.6%
Annualized
90-Day Vol
354.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$9.21
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.17 | C$1.13 – C$59.34 |
| 60 trading days | C$8.67 | C$0.53 – C$143.15 |
| 90 trading days | C$9.21 | C$0.30 – C$285.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
COSCIENS Biopharma Inc. Reports 1D Change of 0.00%, 1W Change of +1.99%
The stock's performance over the past month shows a remarkable increase of 160.14%, but recent trading volume indicates a lack of active trading interest compared to its average.
Bull case
The recent consolidation and share split may improve liquidity and attract new investors. Additionally, the reported net income of $10.8 million in Q1 2026 suggests potential for recovery as the company transitions post-merger.
Bear case
The significant gap between current prices and moving averages indicates a lack of momentum. Furthermore, the company's negative return on equity raises concerns about long-term profitability amid ongoing operational challenges.
Recent Price Action
COSCIENS Biopharma Inc. closed at C$7.70, showing no change in price for the day. Over the past week, the stock has increased by 1.99%, while it has surged by 160.14% in the last month and 165.52% year-to-date. This substantial growth highlights the volatility and potential for rapid changes in investor sentiment.
Company News and Developments
No significant company news has emerged this week. However, COSCIENS recently completed a share capital amendment, consolidating shares on a 1-for-150 basis and subsequently implementing a 50-for-1 split. This restructuring aims to improve liquidity and attract new investors, though the market's response remains to be seen.
Technical Picture
Analyzing the technical indicators, COSCIENS Biopharma's current price is significantly below both its 50-day moving average of C$20.16 and its 200-day moving average of C$23.77, indicating a bearish trend. The stock is trading within 48% of its 52-week range, which spans from C$1.10 to C$14.80. The beta of 1.90 suggests higher volatility compared to the market, and the current trading volume of 414 shares is only 25% of the 20-day average volume of 1,632 shares.
Insider Activity
No insider activity has been reported for COSCIENS Biopharma Inc. during this period, which may indicate a lack of significant confidence or concern among insiders regarding the company's current direction.
Price Action Summary
As of the last close, COSCIENS Biopharma Inc. is trading at C$7.70, reflecting a 1D change of 0.00%. Investors should keep an eye on upcoming developments and financial results as they could impact future price movements.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
